Evaluation of Myocardial Viability : Dual Energy Cardiac CT vs. Cardiac MRI
NCT ID: NCT02360150
Last Updated: 2016-08-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
45 participants
INTERVENTIONAL
2015-02-28
2018-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This would allow the patient to avoid duplication of tests including risk related to coronary angiography (bleeding complications, stroke ...) and those related to the implantation of coronary stent (stent) without expected earnings in case of non-viability . This would also reduce the length of hospital stay and costs due to numerous reviews.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low-Dose Dobutamine Tc-99m-Mibi Gated SPECT to Predict Left Ventricular Remodelling in Patients Reperfused in the Acute Phase of MI
NCT00487812
MRI Evaluation of Chest Pain
NCT00001961
Relationship Between CMR-derived Parameters of Ischemia / Reperfusion Injury and Timing of CMR in STEMI
NCT03522116
The Supplementary Role of Non-invasive Imaging to Routine Clinical Practice in Suspected Non-ST-elevation Myocardial Infarction
NCT01559467
Myocardial Contrast Echocardiography for the Assessment of the Infarct Related Artery & Risk Area in Patients w/ NSTEMI.
NCT02014701
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The experimental procedure is limited to a second CT acquisition performed 10 minutes in dual energy mode.
Sensitivity and Specificity of delayed enhancement \>50% of myocardial thickness provided by dual-energy CT will be evaluated in comparison to cardiac MRI.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
second propeller arm scanner
The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement to the inclusion visit.
second propeller arm scanner
The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
second propeller arm scanner
The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Major patient
* Patient with electrical, biological and clinical signs of myocardial infarction, with late presentation (\>24 hours)
* Creatinine clearance (calculated using the Cockcroft (\<age 65) or MDRD (\> 65 years))formula \> 30 ml / min.
* Affiliation to the french social security scheme.
* Women of childbearing age: Negative pregnancy test (urine test).
* Postmenopausal women, menopause confirmation of diagnosis
* Patient able to understand the spoken and written French.
* Signature of informed consent
Exclusion Criteria
* Arrhythmia and/or non-reducible tachycardia.
* History of allergic reaction after iodinated contrast medium injection.
* History of nephrogenic systemic fibrosis.
* History of claustrophobia
* Unbalanced asthma.
* Acute pulmonary edema.
* Pregnant or breastfeeding women.
* Clinical signs of thyrotoxicosis.
* Person placed under judicial protection,
* Patient suffering from serious psychiatric disease.
* Patients participating in another clinical trial.
* Contraindication to MRI
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Rouen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Benjamin DUBOURG, Doctor
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Rouen
Jean-Nicolas DACHER, Professor
Role: STUDY_DIRECTOR
University Hospital, Rouen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital of Rouen
Rouen, Normandy, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013/205/HP
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.